Payment overview · 2025
General Payments
$250.62
12 reported records · 10 companies
Healthcare provider profile · identity verified
Terry G Daniel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EDEN, NC · NPI 1578565776
Verified facts
What the public records show
CMS Open Payments records show Terry G Daniel, M.D. received $250.62 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.72 | 23.0% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $39.01 | 15.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.58 | 9.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.43 | 8.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.25 | 8.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.95 | 8.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.87 | 8.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.18 | 6.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.11 | 6.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.62 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.72 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 886 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 597 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 595 | 136 |
| Omeprazole | Omeprazole | 576 | 128 |
| Duloxetine Hcl | Duloxetine Hcl | 573 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 541 | 121 |
| Losartan Potassium | Losartan Potassium | 532 | 116 |
| Gabapentin | Gabapentin | 496 | 114 |
| Metformin Hcl Er | Metformin Hcl | 454 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 451 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 90 |
| Alprazolam | Alprazolam | 386 | 60 |
| Lisinopril | Lisinopril | 370 | 80 |
| Furosemide | Furosemide | 366 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 67 |
| Glipizide Er | Glipizide | 295 | 66 |
| Simvastatin | Simvastatin | 289 | 65 |
| Eliquis | Apixaban | 263 | 41 |
| Allopurinol | Allopurinol | 249 | 58 |
| Tramadol Hcl | Tramadol Hcl | 245 | 46 |
| Potassium Chloride | Potassium Chloride | 232 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 53 |
| Sertraline Hcl | Sertraline Hcl | 220 | 49 |
| Clonazepam | Clonazepam | 195 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 42 |
| Trazodone Hcl | Trazodone Hcl | 195 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 193 | 122 |
| Alendronate Sodium | Alendronate Sodium | 174 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 36 |
| Prednisone | Prednisone | 166 | 105 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 18 |
| Buspirone Hcl | Buspirone Hcl | 149 | 28 |
| Lorazepam | Lorazepam | 148 | 24 |
| Famotidine | Famotidine | 144 | 32 |
| Ezetimibe | Ezetimibe | 140 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 33 |
| Bupropion Xl | Bupropion Hcl | 126 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 23 |
| Mirtazapine | Mirtazapine | 126 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 123 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 31 |
| Topiramate | Topiramate | 119 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 38 |
| Jardiance | Empagliflozin | 114 | 26 |
| Montelukast Sodium | Montelukast Sodium | 111 | 27 |
| Donepezil Hcl | Donepezil Hcl | 110 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 16 |
| Atenolol | Atenolol | 101 | 20 |
| Spironolactone | Spironolactone | 101 | 26 |
| Metformin Hcl | Metformin Hcl | 99 | 18 |
| Xarelto | Rivaroxaban | 93 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 23 |
| Meloxicam | Meloxicam | 89 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 36 |
| Ozempic | Semaglutide | 86 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 22 |
| Mounjaro | Tirzepatide | 84 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 84 | 18 |
| Valsartan | Valsartan | 78 | 17 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 76 | 69 |
| Carvedilol | Carvedilol | 75 | 22 |
| Lovastatin | Lovastatin | 75 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 38 |
| Aripiprazole | Aripiprazole | 65 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 12 |
| Diazepam | Diazepam | 62 | 11 |
| Azithromycin | Azithromycin | 61 | 56 |
| Colchicine | Colchicine | 58 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 55 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 53 | 53 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 41 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 21 |
| Finasteride | Finasteride | 48 | 11 |
| Fluconazole | Fluconazole | 48 | 30 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Baclofen | Baclofen | 46 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 11 |
| Estradiol | Estradiol | 46 | 14 |
| Risperidone | Risperidone | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 40 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 37 |
| Nystatin | Nystatin | 43 | 27 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Fentanyl | Fentanyl | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 27 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Linzess | Linaclotide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Rybelsus | Semaglutide | 27 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 18 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Teriparatide | Teriparatide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.62 · 12 records | ABBVIE INC. | APTIMA, Cologuard Collection Kit, JARDIANCE, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, Veozah, Wegovy, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error